Global results validating AFP-L3, AFP and DCP using the GALAD model were presented at the EASL 2015 meeting
During the EASL meeting “The International Liver Congress®” on 22-26 April 2015 researchers from the University of Liverpool (UK) and the University of Turin (Italy) presented study results on the HCC biomarkers AFP-L3 and DCP. Both investigations included the GALAD model for improved hepatocellular carcinoma (HCC) risk determination.
Berhane et al. validated the statistical GALAD model including Gender, Age, AFP-L3, AFP and DCP in an international setting by analysing cohorts from UK, Germany and Japan. AUROC analysis in all three cohorts showed better values for GALAD compared to individual or combined markers. Within each cohort the utility of the model was only slightly lower in smaller tumors. The model performance did not vary between the aetiologies HBV, HCV and “others”. The authors concluded that the initially UK developed GALAD model has now been successfully validated in cohorts from Germany and Japan. The potential role of this model in clinical surveillance will need to be assessed.
Here you can download the poster presented at the EASL meeting which has been provided by courtesy of the authors (Berhane et al.).
Abate et al. evaluated the diagnostic accuracy of AFP, AFP-L3 and DCP alone, in combination and in the GALAD model for HCC detection in an Italian cohort. 44 patients with chronic liver disease but without HCC and 54 HCC patients (85% BCLC stage 0/A) were retrospectively enrolled. The combination of all three markers resulted in statistically significant higher AUC values than any marker alone. The GALAD model showed with 0,976 the highest AUC value. In conclusion the superior diagnostic performance of the marker combination and GALAD model were confirmed.
Here you can download the poster presented at the EASL meeting which has been provided by courtesy of the authors (Abate et al.).
If you would like to learn more about Wako's HCC Biomarker, please download the HCC Biomarker Flyer here.